42 U.S.C. § 284j — Muscular dystrophy research
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
(a) Coordination of activities The Director of NIH shall expand and increase coordination in the activities of the National Institutes of Health with respect to research on muscular dystrophies, including Duchenne muscular dystrophy. (b) Administration of program; collaboration among agencies The Director of NIH shall carry out this section through the appropriate institutes, including the National Institute of Neurological Disorders and Stroke and in collaboration with any other agencies that the Director determines appropriate. (July 1, 1944, ch. 373, title IV, § 409F, as added Pub. L. 106–310, div. A, title XXII, § 2201 , Oct. 17, 2000 , 114 Stat. 1157 ; amended Pub. L. 109–482, title I, § 103(b)(12) , Jan. 15, 2007 , 120 Stat. 3687 .) Editorial Notes Amendments 2007—Subsec. (c). Pub. L. 109–482 struck out heading and text of subsec. (c). Text read as follows: “There are authorized to be appropriated such sums as may be necessary to carry out this section for each of the fiscal years 2001 through 2005. Amounts appropriated under this subsection shall be in addition to any other amounts appropriated for such purpose.” Statutory Notes and Related Subsidiaries Effective Date of 2007 Amendment Amendment by Pub. L. 109–482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109–482 , set out as a note under section 281 of this title .
Related documents
- 42 U.S.C. § 283g — Muscular dystrophy; initiative through Director of National Institutes of Health#595201
- Duchenne muscular dystrophy disease severity impacts skeletal muscle progenitor cells systemic delivery#492037
- 42 U.S.C. § 247b-18 — Surveillance and research regarding muscular dystrophy#595381
- An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)#891254
- Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy#834914
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive